{"id":499427,"date":"2022-12-07T09:21:34","date_gmt":"2022-12-07T11:21:34","guid":{"rendered":"https:\/\/teknomers.com\/fr\/morphosys-shares-stronger-licence-accordee-pour-un-programme-preclinique-en-oncologie\/"},"modified":"2022-12-07T09:21:35","modified_gmt":"2022-12-07T11:21:35","slug":"morphosys-shares-stronger-licence-accordee-pour-un-programme-preclinique-en-oncologie","status":"publish","type":"post","link":"https:\/\/teknomers.com\/fr\/morphosys-shares-stronger-licence-accordee-pour-un-programme-preclinique-en-oncologie\/","title":{"rendered":"MorphoSys Shares Stronger : Licence accord\u00e9e pour un programme pr\u00e9clinique en oncologie"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"BoxNZARN_5_1_1\">\n<p>Pour vous faciliter le suivi du grand nombre de messages qui apparaissent chaque jour pour une entreprise, nous avons divis\u00e9 le fil d&#8217;actualit\u00e9s dans les cat\u00e9gories suivantes\u00a0:<\/p>\n<p><strong>Pertinent:<\/strong> Nouvelles de sources s\u00e9lectionn\u00e9es qui traitent sp\u00e9cifiquement de cette entreprise<\/p>\n<p><strong>Tout:<\/strong> Toutes les actualit\u00e9s li\u00e9es \u00e0 cette entreprise.  Par exemple, les rapports de march\u00e9 qui affectent \u00e9galement d&#8217;autres entreprises<\/p>\n<p><strong>de la soci\u00e9t\u00e9 :<\/strong> Nouvelles et annonces ad hoc publi\u00e9es par l&#8217;entreprise elle-m\u00eame<\/p>\n<p><strong>Groupes de partage:<\/strong> Nouvelles des entreprises appartenant au groupe de pairs<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.finanzen.net\/nachricht\/aktien\/neues-krebs-zielmolekuel-morphosys-aktie-staerker-lizenz-fuer-praeklinisches-onkologie-programm-vergeben-11970162\" rel=\"nofollow noopener\" target=\"_blank\">ttn-fr-28<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pour vous faciliter le suivi du grand nombre de messages qui apparaissent chaque jour pour une entreprise, nous avons divis\u00e9 le fil d&#8217;actualit\u00e9s dans les cat\u00e9gories suivantes\u00a0: Pertinent: Nouvelles de sources s\u00e9lectionn\u00e9es qui traitent sp\u00e9cifiquement de cette entreprise Tout: Toutes les actualit\u00e9s li\u00e9es \u00e0 cette entreprise. Par exemple, les rapports de march\u00e9 qui affectent \u00e9galement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":499428,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[64759,1727,60373,66517,185,130288,4802,130287,46564],"class_list":["post-499427","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance","tag-accordee","tag-licence","tag-morphosys","tag-oncologie","tag-pour","tag-preclinique","tag-programme","tag-shares","tag-stronger"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/499427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/comments?post=499427"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/499427\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media\/499428"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media?parent=499427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/categories?post=499427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/tags?post=499427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}